CJC-1295 isn't found on pharmacy shelves in Yukon or virtually any local market — it's a research-grade peptide supplied via a dedicated online market. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any local market ever offers. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. Use this guide to evaluate CJC-1295 vendors rigorously — the quality evaluation approach outlined here are universal across all research contexts.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Yukon comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Vetting CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Positive vendor signals beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Yukon
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Temperature excursions — even temporary temperature deviation — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. Bacterial endotoxin contamination is the primary safety concern associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. The research literature on CJC-1295 should be reviewed carefully before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
